Next Article in Journal
Genome Editing for the Understanding and Treatment of Inherited Cardiomyopathies
Next Article in Special Issue
High-Density Lipoprotein (HDL) Inhibits Serum Amyloid A (SAA)-Induced Vascular and Renal Dysfunctions in Apolipoprotein E-Deficient Mice
Previous Article in Journal
Love at First Taste: Induction of Larval Settlement by Marine Microbes
Previous Article in Special Issue
The Role and Function of HDL in Patients with Chronic Kidney Disease and the Risk of Cardiovascular Disease

Advances in HDL: Much More than Lipid Transporters

by 1,2, 1,3,4,† and 1,3,*,†
Cardiovascular ICCC Program, Research Institute-Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau, 08001 Barcelona, Spain
School of Medicine, University of Barcelona (UB), 08001 Barcelona, Spain
Centro de Investigación Biomédica en Red Cardiovascular (CIBERCV) Instituto de Salud Carlos III, 28001 Madrid, Spain
Cardiovascular Research Chair, Universidad Autónoma Barcelona (UAB), 08001 Barcelona, Spain
Author to whom correspondence should be addressed.
Both authors equally coordinated the work.
Int. J. Mol. Sci. 2020, 21(3), 732;
Received: 10 December 2019 / Revised: 17 January 2020 / Accepted: 19 January 2020 / Published: 22 January 2020
High Density Lipoprotein (HDL) particles, beyond serving as lipid transporters and playing a key role in reverse cholesterol transport, carry a highly variable number of proteins, micro-RNAs, vitamins, and hormones, which endow them with the ability to mediate a plethora of cellular and molecular mechanisms that promote cardiovascular health. It is becoming increasingly evident, however, that the presence of cardiovascular risk factors and co-morbidities alters HDLs cargo and protective functions. This concept has led to the notion that metrics other than HDL-cholesterol levels, such as HDL functionality and composition, may better capture HDL cardiovascular protection. On the other hand, the potential of HDL as natural delivery carriers has also fostered the design of engineered HDL-mimetics aiming to improve HDL efficacy or as drug-delivery agents with therapeutic potential. In this paper, we first provide an overview of the molecules known to be transported by HDL particles and mainly discuss their functions in the cardiovascular system. Second, we describe the impact of cardiovascular risk factors and co-morbidities on HDL remodeling. Finally, we review the currently developed HDL-based approaches. View Full-Text
Keywords: HDL; cardiovascular risk factors; cardiovascular disease; engineered HDL-mimetics HDL; cardiovascular risk factors; cardiovascular disease; engineered HDL-mimetics
Show Figures

Figure 1

MDPI and ACS Style

Ben-Aicha, S.; Badimon, L.; Vilahur, G. Advances in HDL: Much More than Lipid Transporters. Int. J. Mol. Sci. 2020, 21, 732.

AMA Style

Ben-Aicha S, Badimon L, Vilahur G. Advances in HDL: Much More than Lipid Transporters. International Journal of Molecular Sciences. 2020; 21(3):732.

Chicago/Turabian Style

Ben-Aicha, Soumaya, Lina Badimon, and Gemma Vilahur. 2020. "Advances in HDL: Much More than Lipid Transporters" International Journal of Molecular Sciences 21, no. 3: 732.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop